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Abstract
Background: Neuropathic pain is a chronic disease resulting from dysfunction within the “pain matrix”.T h eb a s o l a t e r a l
amygdala (BLA) can modulate cortical functions and interactions between this structure and the medial prefrontal cortex
(mPFC) are important for integrating emotionally salient information. In this study, we have investigated the involvement
of the transient receptor potential vanilloid type 1 (TRPV1) and the catabolic enzyme fatty acid amide hydrolase (FAAH) in
the morphofunctional changes occurring in the pre-limbic/infra-limbic (PL/IL) cortex in neuropathic rats.
Results: The effect of N-arachidonoyl-serotonin (AA-5-HT), a hybrid FAAH inhibitor and TPRV1 channel antagonist,
was tested on nociceptive behaviour associated with neuropathic pain as well as on some phenotypic changes
occurring on PL/IL cortex pyramidal neurons. Those neurons were identified as belonging to the BLA-mPFC
pathway by electrical stimulation of the BLA followed by hind-paw pressoceptive stimulus application. Changes in
their spontaneous and evoked activity were studied in sham or spared nerve injury (SNI) rats before or after
repeated treatment with AA-5-HT. Consistently with the SNI-induced changes in PL/IL cortex neurons which
underwent profound phenotypic reorganization, suggesting a profound imbalance between excitatory and
inhibitory responses in the mPFC neurons, we found an increase in extracellular glutamate levels, as well as the up-
regulation of FAAH and TRPV1 in the PL/IL cortex of SNI rats. Daily treatment with AA-5-HT restored cortical
neuronal activity, normalizing the electrophysiological changes associated with the peripheral injury of the sciatic
nerve. Finally, a single acute intra-PL/IL cortex microinjection of AA-5-HT transiently decreased allodynia more
effectively than URB597 or I-RTX, a selective FAAH inhibitor or a TRPV1 blocker, respectively.
Conclusion: These data suggest a possible involvement of endovanilloids in the cortical plastic changes associated
with peripheral nerve injury and indicate that therapies able to normalize endovanilloid transmission may prove
useful in ameliorating the symptoms and central sequelae associated with neuropathic pain.
Introduction
There is increasing evidence that the unpleasantness or
affective component of pain, similarly to other high-
order cognitive and emotional functions (i.e. decision
making, goal-directed behavior, and working memory)
[1,2], are driven by specific forebrain areas, and, among
these, the prefrontal cortex (PFC) plays a pivotal role. In
particular, the medial prefrontal cortex (mPFC) partici-
pates in signalling the unpleasantness of pain in humans
[3,4], being the affective component of pain under the
control of the anterior cingulate cortex [5,6]. Suprasp-
inal brain regions are profoundly affected by peripheral
nerve injury or spinal nerve transection in rodents [7,8].
Accordingly, patients with chronic back pain showed
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reorganization of the mPFC might occur and account
for the impaired performance of emotional decision
making tasks (i.e. the Iowa Gambling Task) [10] in
patients suffering from complex region pain syndrome
type I (CRPS I) or chronic back pain similarly to
patients with frontal cortex lesions. The extent of activa-
tion of the mPFC during spontaneous pain and the
extent of emotional and cognitive impairment correlates
to the intensity and the duration of the pain condition
in patients suffering from chronic back pain [11].
Human brain imaging studies have thus revealed that
chronic pain is associated with the activation of excita-
tory and inhibitory neurotransmission, neurotrophic fac-
tor transcription and synthesis of proteins involved in
glutamate receptor expression, along with GABAergic
neuron apoptosis and new cortical connection establish-
ment [12]. Enhanced pain perception [13-15] has been
shown to be associated with over-expression of the
NR2B subunit of the NMDA receptor and morphologi-
cal reorganization in the anterior cingulate cortex [10].
Larger NMDA-mediated currents were also observed in
pyramidal cells of the infralimbic cortex in neuropathic
rats, corresponding to the mPFC of primates [16].
Moreover, in a more recent study, local application of
D-cycloserine, an NMDA partial agonist, generated an
anti-allodynic effect closely correlated with the infusion
site in a way that the maximum effect was observed in
the prelimbic (PL) cortex. Chronic pain can clearly
interfere with the mPFC which plays a critical role in
the neurophysiological processes such as a reorganiza-
tion of synaptic and neural functioning [17,18], which in
turn, could be responsible for the impaired effectiveness
of emotional decision making test.
The basolateral amygdala (BLA) can modulate cortical
functions, and interactions between the BLA and mPFC
are important for integrating emotionally salient infor-
mation [19-24]; indeed the activation of BLA can modu-
late the activity of separate subpopolations of mPFC
neurons [25-28]. Recent works have shown that pain-
related plasticity in the central nucleus of the amigdala
(CeA) contributes critically to the emotional affective
component of pain [29-34]. Among the novel targets
identified for chronic pain therapy, the transient recep-
tor potential vanilloid subtype 1 (TRPV1) is attracting
increasing interest, since it plays a central role in the
transduction of pain and the initiation of the neurogenic
inflammatory responses including cancer pain [35-38].
The expression and sensitivity of TRPV1 are enhanced
during inflammation and neuropathic pain leading to a
lowering of the pain threshold [39]. Apart from periph-
eral sensory neurons [36], TRPV1 is also expressed in
the brain [40-44], including those areas involved in pain
processing, such as the periaqueductal grey (PAG) and
cingulate cortex [45,46]. TRPV1 has been shown to be
physiologically active in some nuclei of the central
nervous system [47,48]. Based on recent evidence that
N-arachidonoyl-serotonin (AA-5-HT, a unique com-
pound with the “dual” ability to inhibit fatty acid amide
hydrolase [FAAH], the catabolic enzyme of endocanna-
binoids/endovanilloids, and antagonize TRPV1), shows
analgesic activity in acute or chronic pain models in
r o d e n t s[ 4 9 , 5 0 ] ,i nt h i ss t u d yw eh a v ei n v e s t i g a t e dt h e
effect of repeated systemic administration of AA-5-HT
on: i) inhibitory and excitatory activity of the perilimbic/
infra-limbic (PL/IL) cortex neurons, be it spontaneous,
or evoked by electrical stimulation of the BLA, or by
mechanical stimulation of the hind paw; ii) extracellular
glutamate and GABA levels in PL/IL cortex in awake
rats; and iii) phenotypic changes of inhibitory and exci-
tatory PL/IL cortex neurons in SNI rats. Moreover, we
assessed FAAH and TRPV1 expression and endovanil-
loid levels in the PL/IL cortex of sham and neuropathic
rats, and the mechanical allodynia associated with neu-
ropathic pain after a single intra mPFC administration
of vehicle or AA-5-HT.
Materials and methods
Animals and surgery
Male Wistar rats (220-250 g) were housed 3 per cage
under controlled illumination (12:12 h light:dark cycle;
light on 06.00 h) and standard environmental conditions
(ambient temperature 20-22°C, humidity 55-60%) for at
least 1 week before the commencement of experiments.
Rat chow and tap water were available ad libitum.T h e
experimental procedures were approved by the Animal
Ethics Commitee of the Second University of Naples.
Animal care was in compliance with Italian (D.L. 116/92)
and EEC (O.J. of E.C. L358/1 18/12/86) regulations on
the protection of laboratory animals. All efforts were
made to minimise animal suffering and to reduce the
number of animals used.
Mononeuropathy was induced through spinal nerve
ligation (SNI) according to the method of Decostered
and Woolf [51]. Rats were anaesthetized with sodium
pentobarbital (50 mg/kg i.p.). The sciatic nerve was
exposed at mid-thigh level distal to the trifurcation and
freed of connective tissue; the three peripheral branches
(sural, common peroneal, and tibial nerves) of the sciatic
nerve were exposed without stretching nerve structures.
Both tibial and common peroneal nerves were ligated
and transected together. The sham procedure consisted
of the same surgery without ligation and transection of
the nerves.
Treatments
For in vivo extracellular recording experiments groups
(n = 10) of sham and SNI rats were treated for 7 days
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i.p.). Groups (n = 8-10) of sham and SNI rats were used
for the assessment of mechanical allodynia 7 days after
surgery before and after a single intra-cortex microinjec-
tions of vehicle (0.5% DMSO in ACSF), AA-5-HT
(0.1-0.25-1 nmol), URB597 (1-2-4 nmol), I-RTX (0.25-0.5-
1 nmol) or AM251 (0.25-0.5 nmol). Moreover, additional
groups of sham and SNI rats treated with vehicle and
following behavioural tests for ascertaining the occurrence
of allodynia in SNI rats, were divided into three further
groups (n = 3) for RT-PCR, western blot and immunohis-
tochemistry. Finally, for the microdialysis experiments
sham (n = 7) and SNI rats (n = 8) have been tested 7 days
after surgery.
Nociceptive behaviour (allodynia)
Mechanical allodynia was measured by using Dynamic
Plantar Aesthesiometer (Ugo Basile, Varese, Italy). Rats
w e r ea l l o w e dt om o v ef r e e l yi no n eo ft h et w oc o m p a r t -
ments of the enclosure positioned on the metal mesh sur-
face. Rats were adapted to the testing environment before
any measurement was taken. The mechanical stimulus
was then delivered to the plantar surface of the hind paw
of the rat from below the floor of the test chamber by an
automated testing device. A steel rod (2 mm) was pushed
with ascending force (0-30 g in 10 sec). When the animal
withdrew its hind paw, the mechanical stimulus was auto-
matically withdrawn and the force recorded to the nearest
0.1 g. Nociceptive responses for mechanical sensitivity
were expressed as mechanical withdrawal threshold
(MWT) in grams.
Sham and SNI rats received a single administration of
vehicle, AA-5-HT (0.1-0.25-1 nmol), URB597 (1-2-4
nmol), I-RTX (0.25-0.5-1 nmol) or AM251 (0.25-0.5
nmol) into the PL/IL cortex 7 day after the sciatic nerve
insult. The AA-5-HT dose was chosen based on our
previous study in which it proved to be effective in sev-
eral pain models in rodents [49]. Each rat served as its
own control, the responses being measured both before
and after vehicle or drug administration. MWT was
quantified by an observer who was blind to the
treatment.
In vivo single unit extracellular recording
Rats for electrophysiological recordings were anaesthe-
tised with pentobarbital (50 mg/kg, i.p.) and placed in a
stereotaxic device (David Kopf Instruments, Tujunga,
CA, USA). Body temperature was maintained at 37°C
with a temperature-controlled heating pad. In all surgi-
cal preparations, the scalp was incised and holes were
drilled in the skull overlying the site of recording, mPFC
(AP: +3.8-2.7, L: 0.5-0.8 and V: 2.2-5.5 mm), and the
site of stimulation, BLA (AP: -2.5 -3.1, L: 4.5-5.0 and
V: 7.2-9) (Figure 1) according to the coordinates from
Paxinos and Watson [52] and contralateral with
respect to the nerve insult. Anaesthesia was maintained
with a constant, continuous infusion of propofol (5-10
mg/kg/h, i.v.) and a bipolar concentric electrode (NEX-
100; Rhodes Medical Instruments Inc., Summerland,
CA) connected to A320 stimulator (World Precision
Instruments England) was lowered into the caudal
region of the BLA according to Floresco and Tse [53].
After lowering the stimulating electrode into the BLA
(Figure 1A), a glass-insulated tungsten filament
electrode (3-5 MΩ) (FHC Frederick Haer & Co., ME,
USA) was stereotaxically lowered into the mPFC
(Figure 1B). The recorded signals were amplified and
displayed on a digital storage oscilloscope to ensure
that the unit under study was unambiguously discrimi-
nated throughout the experiment. Signals were also fed
into a window discriminator, whose output was pro-
cessed by an interface CED 1401 (Cambridge Electro-
nic Design Ltd., UK) connected to a Pentium III PC.
Spike2 software (CED, version 4) was used to create
peristimulus rate histograms on-line and to store and
analyse digital records of single unit activity off-line.
Configuration, shape, and height of the recorded action
potentials were monitored and recorded continuously
using a window discriminator and Spike2 software for
on-line and off-line analysis.
This study only included neurons with a regular spik-
ing pattern and a spontaneous firing rate between 0.4
and 1.5 Hz, which were classified as pyramidal neurons
[53-55]. Once a neuron was encountered in the mPFC,
the position of the microelectrode was adjusted to
maximize the spike amplitude relative to background
noise. We then delivered electrical stimuli into the BLA
(700 μA) at 2 sec intervals. At least 50 single pulses
were delivered to generate peristimulus time histograms
(PSTHs). Once the cell was identified, mechanical sti-
muli were applied to the hind paw (contralateral to the
mPFC) by using a home made spring-operated forceps
that closed with a force (>500 and <2000 g/10 mm
2)
calibrated with a tension spring balance and delivered
for 5 sec [56]. By using electrical (BLA) or mechanical
(hind paw) stimuli we were able to determine whether
each individual neuron was inhibited, excited or showed
no response to stimulation. We did not record data for
neurons that displayed no change in firing as a result of
stimulation and continued the cell-searching procedure.
Characterization of BLA-evoked responses and
stimulation protocol
We observed that BLA stimulation could evoke two dis-
tinct types of firing changes in separate populations of
mPFC responding neurons .T h em o r ec o m m o n l y
observed response was a robust inhibition of neural
activity. We characterized these responses accordingly
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Nakamura [26]. Specifically, a cell was considered to be
inhibited by BLA stimulation if it displayed a complete
cessation of spontaneous firing after BLA stimulation.
Neurons displaying this type of response are referred to
hereafter as BLA®mPFC(-) neurons [53]. Only neurons
that displayed a spontaneous firing rate of between 0.5
and 1.5 Hz were used for the data analysis.
Once a neuron that was inhibited by BLA stimulation
was isolated, single-pulse stimulation was delivered at
•AP: +3.8-2.7
• L: 0.5-0.8
• V: 2.2-5.5 mm
A
B
0.5 Hz
700 ȝA
PL 
IL
Figure 1 Representative schematic illustration showing the location of the recording electrode in the PL/IL cortex and of the
stimulation electrode in the BLA (A). Number values refer to stimulation parameters. Abbreviations: CEA, central nucleus of amygdala; BLA,
basolateral nucleus of amygdala; VTA, ventral tegmental area; PAG, periaqueductal gray; DR, dorsal raphe nucleus; PL, prelimbic cortex; IL,
infralimbic cortex; MO, medial orbital cortex; PRC, perirhinal cortex. Reprinted from Vertes [99]. Schematic illustration of the PL/IL cortex recording
sites (B). Filled circles represent mPFC cell recorded sites. Number values indicate distance to bregma.
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Page 4 of 190.5 Hz. We typically used 100-250 sweeps and peristi-
mulus time histograms were generated on-line. We used
two parameters derived from the peristimulus time his-
tograms to assess differences between different groups
of rats. Our primary measure was the “duration” of inhi-
bition (ms) as defined by Ishikawa and Nakamura [26].
The duration was calculated from the longest period
when spontaneous firing was completely suppressed
after BLA stimulation. The second measure we have
considered here was the “onset” of this period of inhibi-
tion (ms) after BLA stimulation (the time interval
between the stimulus application and last spike before a
complete cessation of neuronal activity). By using
these parameters we could have a reliable index of
BLA-evoked inhibition and changes in the inhibitory
influences that BLA inputs exert over the mPFC neuron
firing. An example of a typical inhibitory response
recorded from a BLA ® mPFC(-) neuron is shown in
Figure 2A
A second group of neurons displaying a fast-onset
burst of firing were classified as BLA ® mPFC(+) neu-
rons. This group of neurons showed a cluster of spikes
typically showing a Gaussian pattern of distribution and
appeared to have an increased probability of spike firing
after BLA stimulation (700 μA). From the peristimulus
time histograms we measured the “duration” of excita-
tion (in ms) as the period of the increased firing activity
which exceeds the average baseline value + 2 standard
deviation (SD). Moreover, we measured the frequency of
evoked excitation and the onset of excitation which was
considered as the time from the application of the sti-
mulus (artefact) to the first evoked spike which exceeds
the average baseline value + 2 SD. The onset of burst
(ms) was calculated as the time interval between the
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Figure 2 BLA stimulation evokes inhibitory responses in the PL/IL cortex of BLA ® PL/IL (-) neurons. The figure shows different
parameters of BLA-evoked inhibition, including the onset and duration of the inhibition, in sham and SNI rats treated for 7 days with vehicle
(veh) or AA-5-HT (5 mg/kg, i.p.). “A”, “B” and “C” show representative ratemater records of a BLA ® PL/IL (-) neurons of sham/veh, SNI/veh or
SNI/AA-5-HT rat, respectively. “D” and “E” show the onset and duration (mean ± SEM) of the inhibition, respectively, in different groups of rats.
* indicates statistically significant difference versus sham/veh and º versus SNI/veh. P < 0.05 was considered as value of significance and n = 10
was used for each group.
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Page 5 of 19stimulus application and the first evoked spike of the
burst [22,57]. These criteria were used as an index of
changes in the excitatory influence that BLA inputs
exert over mPFC neuron firing. An example of a typical
excitatory response recorded from a BLA ® mPFC(+)
neuron is shown in Figure 3A.
Characterization of mechanical-evoked responses
Mechanical stimuli were applied to the hind paw
(contralateral to the mPFC) by a spring-operated for-
ceps with a force (>500 and <2000 g/10 mm
2)w h i c h
squeezed the tissue (painful pressure). The stimulus
duration was 5 sec. The mechanical stimulus evoked
inhibitory or excitatory response in separate popula-
tions of mPFC neurons. The same parameters of the
inhibitory and excitatory responses were measured
a n dc o n s i d e r e da sa ni n d e xo fm P F Cn e u r o nf i r i n g
response to mechanical noxious stimuli. An example
of a typical inhibitory and excitatory response
recorded from a mechanical stimulation on mPFC (-)
and mPFC (+)neurons is shown in Figure 4A and 5A
respectively.
In vivo microdialysis
Brain microdialysis experiments were performed in
awake and freely moving rats. In brief, rats were anaes-
thetised with pentobarbital (50 mg/kg, i.p.) and stereo-
taxically implanted with concentric microdialysis probes
into the mPFC using coordinates: AP: +3.8-2.7 mm,
L: 0.4-0.7 mm from bregma and V: 5.3 mm below the
dura. Microdialysis concentric probes were constructed
as described by Hutson et al., [58] with 25 G (0.3 mm I.D.,
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Figure 3 BLA stimulation evokes excitatory responses in the PL/IL cortex of BLA ® PL/IL (+) neurons. The figure shows different
parameters of BLA-evoked excitation, including the onset, the frequency and the duration of excitation, in sham and SNI rats treated for 7 days
with vehicle (veh) or AA-5-HT (5 mg/kg, i.p.). “A”, “B” and “C” show a representative ratemater record of a BLA ® PL/IL (+) neurons of sham/veh,
SNI/veh and SNI/AA-5-HT rat. “D”,"E” and F show the onset, onset, the frequency and the duration (mean ± SEM) of the excitation, respectively,
in the different groups of rats. * indicates statistically significant difference versus sham/veh and º versus SNI/veh. P < 0.05 was considered as
value of significance and n = 10 was used for each group.
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Page 6 of 190.5 mm O.D.) stainless steel tubing: inlet and outlet
cannulae (0.04 mm I.D., 0.14 mm O.D.) consisted of
fused silica tubing (Scientific Glass Engineering,
Melbourne, Australia). The microdialysis probe had
a tubular active membrane (Enka AG, Wuppertal,
Germany) of 3 mm in length. Following a post-opera-
tive recovery period of approximately 24 hrs, probes
were perfused with artificial cerebrospinal fluid (ACSF,
composition in mM: NaCl, 125; KCl, 2.5; MgCl2,1 . 1 8
and CaCl2, 1.26) at a rate of 0.8 μl/min using a Harvard
Apparatus infusion pump (mod. 22). After an initial
60 min equilibration period, dialysate samples were col-
lected every 30 min for and 2.5 hrs to establish baseline
release of glutamate and GABA in sham and SNI rats.
Groups of rats received tetrodotoxin (TTX, 1 μM), or
calcium-free ACSF, by reverse microdialysis to assess the
synaptic nature of glutamate and GABA in mPFC cortex
dialysates. On completion of experiments, rats were
anaesthetised with pentobarbital and their brains per-
fused-fixed via the left cardiac ventricle with heparinised
paraformaldehyde saline (4%). Brains were dissected out
and fixed in a 10% formaldehyde solution for 2 days.
Each brain was cut in 40 micron thick slices and
observed under a light microscope to identify the probe
location. Dialysates were analysed for amino acid content
using a high-performance liquid chromatography
(HPLC) method. The system comprised a Varian ternary
pump (mod. 9010), a C18 reverse-phase column, a refri-
gerated autoinjector (mod. 9100), a fluorimetric detector
(mod. PS363). Dialysates were pre-column derivatised
with o-pthaldialdehyde (10 microliter dialysate + 10
microliter o-pthaldialdehyde) and amino acid conjugates
resolved using a gradient separation. The detection limit
of GABA and glutamate in 10 microliter samples was
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Figure 4 Mechanical nociceptive stimulation evokes inhibitory responses in the PL/IL cortex of BLA ® PL/IL (-) neurons.T h ef i g u r e
shows different parameters of mechanical nociceptive stimulation-evoked inhibition, including the onset and duration of the inhibition, in sham
and SNI rats treated for 7 days with vehicle (veh) or AA-5-HT (5 mg/kg, i.p.). “A”, “B” and “C” show a representative ratemater record of a
mechanical stimulus ® PL/IL (-) neurons of sham/veh, SNI/veh and SNI/AA-5-HT rat, respectively. “D” and “E” show the onset and duration
(mean ± SEM) of the inhibition, respectively, in the different groups of rats. * indicates statistically significant difference versus sham/veh and
º versus SNI/veh. P < 0.05 was considered as value of significance and n = 10 was used for each group.
de Novellis et al. Molecular Pain 2011, 7:7
http://www.molecularpain.com/content/7/1/7
Page 7 of 19approximately 0.5-1 and 2-3 pmol, respectively. The
mobile phase consisted of two components: (A) 0.1 M
sodium acetate buffer (pH 6.95), 25% tetrahydrofuran
and 10% methanol and (B) 100% methanol; gradient
composition was determined with a Dell PC installed
with Varian Star gradient management software, and the
mobile phase flow rate was maintained at 1.0 ml/min.
Data were collected by a Dell Corporation PC system 310
interfaced with Varian Star 6.2 control data and acquisi-
tion software. The mean dialysate concentration of
amino acids in the first five samples represents the basal
release in the two different groups of rats.
RNA extraction and RT-PCR
Total RNA was extracted from homogenized mPFC
using an RNA Tri-Reagent (Molecular Research Center
Inc., Cincinnati, OH) according to the manufacturer’s
protocol. The extracted RNA was subjected to DNase I
treatment at 37°C for 30 min. The total RNA concentra-
tion was determined by UV spectrophotometer. The
mRNA levels of the genes under analysis were measured
by RT-PCR amplification, as previously reported [59].
RT minus controls were carried out in order to check
potential genomic DNA contamination. These RT
minus controls were performed without using the
reverse transcriptase enzyme in the reaction mix.
Sequences for the mouse mRNAs from GeneBank
( D N A S T A RI N C . ,M a d i s o n ,W I )w e r eu s e dt od e s i g n
primer pairs for RT-PCRs (OLIGO 4.05 software,
National Biosciences Inc., Plymouth, MN). Each RT-
PCR was repeated at least four times so as to achieve
optimal reproducibility data. A semi-quantitative
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Figure 5 Mechanical stimulation evokes excitatory responses in the PL/IL cortex neurons of BLA ® PL/IL (+) neurons. The figure shows
different parameters of mechanical stimulus-evoked excitation, including the onset, the frequency and the duration of excitation, in sham and
SNI rats treated for 7 days with vehicle (veh) or AA-5-HT (5 mg/kg, i.p.). “A”, “B” and “C” show a representative ratemater record of a mechanical
stimulus ® PL/IL (+) neurons of sham/veh, SNI/veh and SNI/AA-5-HT rat. “D”,"E” and F show the onset, the frequency and the duration (mean ±
SEM) of the excitation, respectively, in the different groups of rats. * indicates statistically significant difference versus sham/veh and º versus SNI/
veh. P < 0.05 was considered as value of significance and n = 10 was used for each group.
de Novellis et al. Molecular Pain 2011, 7:7
http://www.molecularpain.com/content/7/1/7
Page 8 of 19analysis of mRNA levels was carried out using the “Gel
Doc 2000 UV System” (Bio-Rad, Hercules, CA). The
measured mRNA levels were normalised with respect to
b-actin chosen as housekeeping gene. The b-actin gene
expression values were expressed as arbitrary units ±
SE. Amplification of genes of interest and b-actin were
performed simultaneously.
Western Blotting
For the protein extraction, the mPFC was minced into
small pieces with a blender, then was suspended in lysis
buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol,
0.004% blue-bromophenol, Tris-HCl, pH 6.8, containing
6 M urea, 50 μMN a 3VO4,5 0μM PMSF (Sigma Chemi-
cal Co., St. Louis, MO). The total protein concentration
was determined using the method described by Bradford
[60]. Each sample was loaded, electrophoresed in a 12%
polyacrylamide gel and electroblotted onto a nitrocellu-
lose membrane. Primary antibodies were used to detect
TRPV1 and FAAH according to the manufacturer’s
instruction at 1:500 dilution (Santa Cruz; USA). Immu-
noreactive signals were detected with a horseradish per-
oxidase-conjugated secondary antibody and reacted with
an ECL system (Amersham Pharmacia, Uppsala,
Sweden). Protein levels were normalized with respect to
the signal obtained with anti-beta-actin monoclonal
antibodies (Sigma Chemical Co., St. Louis, MO, 1:1000
dilution).
Immunohistochemistry
Under pentobarbital anaesthesia, animals were perfused
transcardially with saline solution (0.9% NaCl) and 4%
paraformaldheyde fixative. The brain was taken out and
kept in the fixative for 24 h at 4°C. The tissue was kept
in 30% sucrose in PBS and frozen in cryostat embedding
medium (Bio-Optica, Milano, Italy). Serial 15 μm
sections of the brain were c u tu s i n gac r y o s t a ta n d
thaw-mounted onto glass slides. After washing in PBS,
non-specific antibody binding was inhibited by incuba-
tion for 30 min in blocking solution (1% BSA, 0.2%
powdered skim milk, 0.3% Triton-X 100 in PBS). Pri-
mary antibodies were diluted in PBS blocking buffer and
slides were incubated overnight at 4°C in primary anti-
bodies to goat polyclonal TRPV1 (1:100, Santa Cruz;
USA) or goat polyclonal FAAH (1:100, Santa Cruz;
USA). Fluorescent-labelled secondary antibodies (1:500;
Alexa Fluor 488, Molecular Probe, Invitrogen, Carlsbad,
CA) specific to the IgG specie used as a primary anti-
body were used to locate the specific antigens in each
section. Sections were counterstained with bisbenzimide
(Hoechst 33258, Hoechst, Frankfurt, Germany) and
mounted with Vectashield mounting medium (Vector
Laboratories, Burlingame, CA). Fluorescently labelled
sections were viewed with a fluorescence microscope
(Leica, Wetzlar, Germany) to locate the cells and iden-
tify the area of the brain.
Analysis of endocannabinoid levels
In order to perform the endocannabinoid analysis, a
different cohort of rats was used. Decapitation was
performed and brains were rapidly removed and
embedded in oxigenated ice-cold artificial cerebrosp-
inal fluid. A PFC slice of 1.30-1.35 mm was cut
throughout the PFC by using a vibrotome (Vibratome
1500, Warner Instruments, CT, USA) (interaural from
+1.9 mm to +0.7 mm) [61]. The obtained slice of tis-
sue containing the mPFC was then further dissected
under optical microscope for microsurgery to isolate
the PL-IL cortex (M650, Wild Heerbrugg, Switzerland)
to be homogenized accordingly to our protocol. In
brief, tissues were homogenized in 5 volumes of
chloroform/methanol/Tris HCl 50 mM (2:1:1) contain-
ing 20 pmol of d
8-AEA and d
5-2-AG. Deuterated stan-
dards were synthesized from commercially available
deuterated arachidonic acid and ethanolamine or gly-
cerol, as described, respectively, in Devane et al. [62]
and Bisogno et al. [63]. Homogenates were centrifuged
at 13,000 × g for 16 min (4°C), the aqueous phase plus
debris was collected and extracted again twice with
1 volume of chloroform. The organic phases from the
3 extractions were pooled and the organic solvents
evaporated in a rotating evaporator. Lyophilized
extracts were re-suspended in chloroform/methanol
99:1 by volumes. The solutions were then purified by
open bed chromatography on silica as described in
Bisogno et al. [63]. Fractions eluted with chloroform/
methanol 9:1 by volume (containing AEA and 2-AG)
were collected, the excess solvent was evaporated with
a rotating evaporator, and aliquots were analysed by
isotope dilution-liquid chromatography/atmospheric
pressure chemical ionization/mass spectrometry (LC-
APCI-MS) carried out under conditions described pre-
viously [64] and allowing the separation of the four
compounds. Mass spectrometric (MS) detection was
carried out in the selected ion monitoring mode using
m/z values of 356 and 348 (molecular ions +1 for
deuterated and undeuterated AEA) and 384.35 and
379.35 (molecular ions +1 for deuterated and undeut-
erated 2-AG). The area ratios between the signals of
the deuterated and undeuterated compounds varied
linearly with varying amounts of undeuterated com-
pounds (30 fmol-100 pmol). AEA and 2-AG levels in
unknown samples were therefore calculated on the
basis of their area ratios with the internal deuterated
standard signal areas. For 2-AG, the areas of the peaks
corresponding to 1(3)-and 2-isomers were added
together. The amounts of endocannabinoids were
expressed as pmol/g or nmol/g of wet tissue weight.
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N-arachidonoyl-serotonin (AA-5-HT) was synthesized in
V. Di Marzo’s laboratory as previously described [65].
5’-Iodoresiniferatoxin (I-RTX), TTX and AM251 were
purchased from Tocris Bioscience (Bristol, UK). 3’-
carbamoylbiphenyl-3yl-cyclohexylcarbamate (URB597)
was purchased from Cayman Chemical Co. (Germany).
All drugs were dissolved in 0.5% DMSO in ACSF.
Statistics
Microdialysis, behavioural and electrophysiology data are
represented as means ± SE and statistical analysis of
these data were performed by two way ANOVA for
repeated measured followed by the Student-Newman-
Keul for multiple comparisons to determine statistical
significance between different treated groups of rats. For
biomolecular analysis, protein quantification and immu-
nohistochemistry the Student-Newman-Keuls and the
Tukey tests have been used, respectively.
Results
Characterization of electrical stimulation-evoked
responses of mPFC neurons
Single-unit extracellular recording in anesthetized rats
was made from individual neurons in the prelimbic or
infralimbic part of the mPFC (Figure 1B). Action poten-
tial duration (540 ± 20 μsec peak-to-valley) and firing
rate (1.1 ± 0.5 spikes/s) from recorded neurons were
consistent with presumed pyramidal cells rather than
fast-spiking interneurons, the latter having a higher
baseline firing rate (>10 Hz) and narrower spike wave-
form (< 300 microsec) [66,22,34].
Electrophysiological properties of BLA-mPFC neurons in
sham and SNI rats
We first investigated the proportion of mPFC neurons
(n = 3-5 per rat) with ongoing activity that responded
with inhibition [BLA®mPFC(-)], or excitation,
[BLA®mPFC(+)]. In these studies, we first isolated
mPFC neurons and thereafter stimulated the BLA at
0.5 Hz using an initial stimulation current of 700 μA.
Whenever a neuron that was responsive to BLA stimu-
lation was encountered, the BLA was stimulated with
100-200 pulses to determine whether the neuron
responded with inhibition or excitation. The same pro-
cedure has been used for four groups of rats: 1) sham
rats treated for 7 days with vehicle (sham/veh); 2)
sham rats treated for 7 days with AA-5-HT (5 mg/kg,
i.p.) (sham/AA-5-HT); 3) SNI rats treated for 7 days
with vehicle (SNI/veh) and 4) SNI rats treated for
7 days with AA-5-HT (5 mg/kg, i.p.). In the control
group (sham/veh), 80% of encountered neurons (n = 32)
displayed an inhibition of spontaneous activity after
BLA stimulation or mechanical stimulation, with the
remaining proportion of cells showing an excitatory
response (n = 8).I nS N I / v e hr a t s ,7 0 %o fn e u r o n s( n
= 28) displayed excitation after BLA or mechanical sti-
mulation, while 30% of cells (n = 12) showed an inhi-
bitory response. The 7 day period of repeated
treatment with AA-5-HT (5 mg/kg, i.p.) in SNI altered
the proportion between BLA®mPFC(-) and BLA®
mPFC(+) neurons. Indeed 67.8% of BLA®mPFC(-)
(n = 27) and 32.2% of BLA®mPFC(+) neurons (n = 13)
were encountered.
BLA®mPFC(-)
In BLA®mPFC(-) neurons the spontaneous firing rate
was 1.1 ± 0.2 spikes/sec, the onset of BLA-evoked inhi-
bition was 83.3 ± 7 ms and the duration of the inhibi-
t i o nw a s4 6 3±2 3m si ns h a m / v e hr a t s( 2 A ,Da n dE ) .
Treatment with AA-5-HT (5 mg/kg, i.p.) did not affect
either the firing rate (1.12 ± 0.3 spikes/sec), the duration
of the inhibition or the onset of inhibition of
BLA®mPFC(-) neurons in the shams (not shown).
SNI/veh rats showed an increased firing rate (2.2 ± 0.5
spikes/sec) of BLA®mPFC(-) neurons. The onset of
BLA-evoked inhibition was significantly (P < 0.05)
reduced (32 ± 7.5 ms) in BLA®mPFC(-) neurons of this
group of rats although no statistically significant changes
were observed in the duration of the inhibition (455 ±
15 ms) (Figure 2B, D and 2E).
Treatment with AA-5-HT (5 mg/kg i.p.) for 7 days in
SNI rats (SNI/AA-5-HT) decreased firing rate (1.2 ± 0.5
spikes/sec), caused a significant increase in the onset
(175 ± 5 ms) of BLA-evoked inhibition and a significant
(P < 0.05) decrease in the duration (250 ± 15 ms)
(Figure 2C, D and 2E).
BLA®mPFC(+) neurons
BLA®mPFC(+) neurons had a firing rate of 0.5 ± 0.2
spikes/sec in sham/veh group. The onset, the frequency
and the duration of excitation were 47 ± 2.12 ms, 6.7 ±
0.8 spikes/sec and 380 ± 13.3 ms, respectively (3A, D,
E and F). Sham rats treated for 7 days with AA-5-HT
(5 mg/kg i.p.) did not show changes in the onset, the
frequency and the duration of excitation (not shown)
with respect to sham/veh. Rats which underwent SNI
(SNI/veh,) showed a firing rate of 0.8 ± 0.2 spikes/sec.
The onset of BLA-evoked excitation was significantly
(P < 0.05) reduced (26.4 ± 3.4 ms) in this group of rats.
The duration and the frequency of evoked excitation of
BLA®mPFC(+) increased significantly (672.5 ± 13.43
ms and 10.3 ± 1.16 spikes/sec, respectively) in this
group of rats (SNI/veh) (Figure 3B, D, E and 3F). Treat-
ment with AA-5-HT (5 mg/kg i.p.) for 7 days in SNI rats
caused a significant increase in the onset (46.8 ± 7.8 ms)
and a significant reduction in the duration and the
frequency of evoked excitation of BLA®mPFC(+)
de Novellis et al. Molecular Pain 2011, 7:7
http://www.molecularpain.com/content/7/1/7
Page 10 of 19n e u r o n s( 3 7 5±1 6 . 3 7m sa n d7 . 7±0 . 3 1s p i k e s / s e c ,
respectively) (Figure 3C, D, E and 3F).
Mechanical stimulation-evoked responses of BLA-mPFC
neurons in sham or SNI rats
This cell population, previously identified by BLA elec-
trical stimulation as BLA®mPFC(-) neurons, responded
accordingly to noxious mechanical stimuli with an inhi-
bition. The onset and duration of the mechanical stimu-
lation-evoked inhibition was 93.7 ± 4.7 and 480 ± 23 ms,
respectively (Figure 4A, D, E) in sham/veh rats. Treat-
ment with AA-5-HT (5 mg/kg) did not affect either the
duration or the onset of mechanical stimulation-evoked
inhibition in the shams (sham/AA-5-HT). In the SNI/veh
group of rats the onset of mechanical stimulation-evoked
inhibition and its duration (60 ± 10 and 385 ± 9.5 ms,
respectively), were significantly reduced (Figure 4B,
D/figr> and 4E). Treatment with AA-5-HT (5 mg/kg i.p.)
for 7 days in SNI rats caused a significant increase in the
onset (210 ± 5.7 ms) and in the duration (550 ± 10 ms)
of the mechanical stimulation-evoked inhibition
(Figure 4C, D and 4E).
Mechanical stimulation-evoked responses of mPFC
BLA®mPFC(+)neurons
This cell population, preliminarily identified by BLA
electrical stimulation as BLA®mPFC(+) neurons,
responded accordingly to noxious mechanical stimuli
with an excitatory response. The onset, the frequency
and the duration of excitation of these mPFC neurons
were 97 ± 8.5 ms, 400 ± 15 ms and 7.4 ± 1.2 spikes/sec,
respectively in the sham/veh (Figure 5A, D, E and 5F)
group of rats. Treatment with AA-5-HT (5 mg/kg, i.p.)
did not affect either duration, onset and frequency of
mechanical stimulation-evoked excitation in the shams
(sham/AA-5-HT) (not shown).
SNI/veh rats showed a significantly reduced onset (65
± 12.2 ms) and an increased duration and frequency of
mechanical stimulation-evoked excitation (600 ± 10 ms
and 12 ± 1.1 spikes/sec, respectively) (Figure.5B, D, E,
F). Treatment for 7 days with AA-5-HT (5 mg/kg i.p.)
caused a significant reduction in the duration (280 ±
12.2 ms) and frequency (6.2 ± 2.2 spikes/sec) of excita-
tion in SNI/veh rats, whereas no change was observed
in the onset (70 ± 2.8 ms) of mechanical stimulation-
evoked excitation (Figure 5C, D, E and 5F).
Microdialysis
The values of extracellular level of glutamate in PL/IL
cortex were measured in pmol in 10 μl (pmol/10 μl). In
vitro recovery of the microdialysis probe for glutamate
was 22 ± 5%. The mean basal value for glutamate within
the mPFC was 30.5 ± 6.2 pmol/10 μl. In sham rats (n = 7),
the extracellular glutamate level in the mPFC did not
change (27.3 ± 5.5 pmol/10 μl). Instead, the extracellular
glutamate level increased significantly (62.8 ± 8 pmol/10
μl) (n = 8, P < 0.05) in SNI rats (Figure 6A). In vitro
recovery of the microdialysis probe for GABA was 21 ±
4%. The mean basal values (not corrected for probe
recovery) of extracellular GABA level in the mPFC were
32.5 ± 5.7 pmol/10 μl. The mPFC extracellular GABA
was unchanged in sham and SNI rats as compared to the
naives (Figure 6A).
TRPV1 and FAAH expression in sham and neuropathic
rats
We have observed that both targets of the AA-5-HT:
the TRPV1 channel and FAAH were up-regulated in
SNI as compared to the sham rats in the PL/IL cortex.
In particular, we found that TRPV1 upregulation only
occurred at the protein level, while mRNA levels
did not increase significantly in neuropathic animals
(Figure 7A, B, C). Conversely, FAAH mRNA levels were
up-regulated, as well as the protein expression in the
layer II-III of PL/IL cortex in neuropathic SNI animals,
also indicating a possible change in the endocannabinoid
turnover (Figuer 8A, B, C). Immunohistochemical data
were obtained from the sham and SNI rats without any
brain lesion.
Intra-cortex microinjections of AA-5-HT, AM251, I-RTX or
URB597 transiently inhibited allodynia in SNI rats
SNI of the sciatic nerve resulted in a significant decrease
in mechanical withdrawal threshold in the ipsilateral
side of rats, though not on the contralateral sides (12.5
± 0.6 g) 7 days after surgery (Figure 9A,B and 9C). A
single microinjection of AA-5-HT (0.1-0.25-1 nmol)
(at day 7 after surgery) into the PL/IL cortex decreased
mechanical allodynia in a dose-dependent manner and
it was apparent up to 85 min after microinjection
(Figuer 9A). This effect was antagonized by the co-injec-
tion with AM251 (0.5 nmol), a CB1 selective antagonist,
while the same dose of AM251 per se did not exert any
significant effect (Figure 9B, C). Conversely, a single
microinjection of I-RTX (0.25-0.5-1 nmol) or URB597
(1-2-4 nmol) (at day 7 after surgery) both proved to be
less effective in decreasing mechanical allodynia, as the
effect lasted no longer than 10-40 min after injection
(Figure 9D, E respectively) in SNI rats.
Endocannabinoid and endovanilloid levels are altered in
the PL/IL cortex of SNI rats
SNI was accompanied by a slight but statistically signifi-
cant decrease in anandamide levels (from 27.2 ± 0.9 to
23.4 ± 0.4 pmol/g wet tissue weight, P < 0.05) in the
PL/IL cortex, whereas the levels of 2-AG were slightly
increased (from 2.1 ± 0.3 to 2.5 ± 0.2 nmol/g wet tissue
weight, P < 0.05) (means ± SEM, N = 5).
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Most studies on pain-related synaptic plasticity have
focused on long-term changes at the peripheral and
spinal dorsal horn neurons [67-74]. Pain-related synaptic
reorganization in cortical areas, including the mPFC,
anterior cingulate cortex (ACC), insular cortex
[17,53,75-78] and BLA [34], and its contribution to pain
processing or to the emotional-affective aspects of pain
[30], has been less investigated. More recently however,
some contrasting data have emerged on the phenotypic
changes of mPFC pyramidal neurons which may depend
on the pain models used. For instance, a large increase
in the NMDA/AMPA ratio of the synaptic currents in
layers II-III of PL/IL neurons, together with specific
dendritic spine proliferation has been found in the SNI
of the sciatic nerve model [16], whereas a massive
mPFC neural deactivation and depression were recently
observed in the arthritic pain model [34].
In the present study, by using integrative methods, we
demonstrate that BLA®mPFC(-) inhibitory and
BLA®mPFC(+) excitatory neurons, which concurrently
respond to the hind-paw pressoceptive stimuli, show
phenotypic changes in SNI-induced mono-neuropathy
in the rat, suggesting that the mPFC may undergo pro-
found reorganization related to chronic pain. Consistent
with data by Metz et al. [16], the current study shows
that SNI can shift the balance of excitatory and inhibi-
tory responses in the BLA®mPFC pathway, resulting in
a net increase in the excitatory influence that the BLA
exerts over the PL/IL neuron population of the mPFC
[30,79,80]. Indeed, whilst in sham rats we found that the
majority (about 80%) of the pyramidal neurons belongs
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Figure 6 “A” shows the release of glutamate and GABA in naïve, sham or SNI rats 7 days after injury. The values of extracellular GABA
and glutamate in the mPFC were expressed as pmol in 10 μl of perfusate. * indicate significant difference vs sham rats. Each point represents
the mean ± S.E.M of 7-8 animals per group. P values < 0.05 were considered statistically significant. “B” shows a panoramic picture of the pre-
frontal cortex, the square indicates the pre/infra-limbic area. “C” shows a high magnification of the microdialysis probe location for aminoacid
collection within the the pre/infra-limbic cortex. Coronal brain slices containing the sites of implantation of the microdialysis probes were
obtained after the experiment and processed for histological analysis.
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remaining part being excitatory neurons of the
BLA®mPFC(+) subtype, in SNI rats such a ratio was
nearly the opposite. One of the main reasons for the
strong presence of inhibitory cells in physiological con-
ditions might be that GABAergic interneurons are
mainly interfaced between BLA-driven excitatory input
and the PL/IL pyramidal neurons of the mPFC [81,82].
Moreover, cortex GABAergic interneurons show a very
strong responsiveness to excitatory inputs because of
the faster AMPA-mediated cationic gating in such inter-
neurons than in excitatory pyramidal cells under basal
conditions [83,84]. Intriguingly, in this study a critical
difference was detected between neuropathic and sham
r a t si nt h ee x c i t a t o r yB L A ®mPFC(+) neurons. A
decrease in the onset, enhancement of frequency and a
longer duration of evoked excitation following ipsilateral
BLA electrical stimulation was observed in this study.
However, our electrophysiological parameters, in parti-
cular as it regards the duration of evoked excitation are
extremely longer than those found by Floresco and Tse
[53] and Laviolette and Grace [22]. Differences among
the anaesthetics used during the electrophysiological
procedures could be responsible of the discrepant
results observed. In particular, Floresco and Tse and
Laviolette and Grace [53,22] have used a high dose of
urethane (1.5 g/kg, i.p. instead of the more conventional
1.2 g/kg, i.p.) for maintaining anaesthesia. Urethane has
a complex multi-target (still poorly known) mechanism
of action such as a non-selective positive modulation of
GABAA and GlyR receptors and a depression of the
NMDA and AMPA glutamate receptors. Indeed, these
anaesthetics very rarely allows a complete recovery from
the anaesthesia. Collectively, the high dose and the
multi-target mechanism of action of it may justify
the decreased duration of the evoked excitation in the
Figure 7 TRPV1 mRNA and protein levels in the pre/infra-limbic cortex of sham and SNI rats. “A” shows the unchanged TRPV1 mRNA
levels normalized vs b-actin in neuropathic vs sham rats. “B” shows the enhanced TRPV1 protein levels normalized vs b-actin in neuropathic vs
sham rats. “C” shows the increased TRPV1 staining in the layer II-III of the rat pre/infra-limbic cortex. Data are represented as a mean ± SEM
n = 3 rats per group. P < 0.05 was considered statistically significant. ANOVA, post hoc Tukey. Scale bars = 100 μm.
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Page 13 of 19pyramidal neurons observed by Floresco and Tse and
Laviolette and Grace [53,22]. In BLA®mPFC(-) neu-
rons, the onset of the inhibition decreased in SNI rats,
suggesting that inhibitory neurotransmission might be
down-regulated in this cortex area during a pathological
painful condition. Indeed, in vivo microdialysis experi-
ments performed here in awake rats showed that the
extracellular levels of glutamate increased in the contral-
ateral mPFC cortex of SNI rats, with no measurable
change in GABA levels under the same experimental
conditions. Overall, these data suggest an SNI-induced
imbalance between the excitatory and inhibitory amino-
acidergic neurotransmissions, resulting in the increased
excitability of the layers II/III pyramidal cells of the
mPFC cortex. Consistently, mechanical noxious stimula-
tion applied to the contralateral paw evoked excitatory
or inhibitory responses in the cell populations previously
identified by BLA electrical stimulation. The application
of noxious stimuli to the contralateral paw of SNI rats
resulted in a decreased onset of burst or pause for the
excitatory or inhibitory cells, respectively. As far as the
other analyzed functional parameters are concerned, an
increased frequency and duration of excitation were
observed following paw mechanical stimulation. Collec-
tively, these in vivo physiological data support recent ex
vivo findings indicating that mPFC pyramidal neurons
undergo profound morpho-functional reorganization
associated with SNI-induced neuropathic pain, support-
ing the possibility of major involvement of the layers
II/III of PL/IL cortex in the patho-physiological pro-
cesses associated with the unpleasant or the affective
component of pain [16]. Although the details of the
pain-related BLA-driven changes justifying the enhanced
excitatory synaptic activity on PL/IL pyramidal cells are
yet to be determined, the pharmacological, electrophy-
siological, biochemical and morphological data from the
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Figure 8 FAAH mRNA and protein levels in the pre/infra-limbic cortex of sham and SNI rats. “A” shows the enhanced FAAH mRNA levels
normalized vs b-actin in neuropathic vs sham rats. “B” shows the enhanced FAAH protein levels normalized vs b-actin in neuropathic vs sham
rats. “C” shows the increased FAAH staining in the layer II-III of the rat pre/infra-limbic cortex. Data are represented as a mean ± SEM n = 3 rats
per group. P < 0.05 was considered statistically significant. ANOVA, post hoc Tukey. Scale bars = 100 μm.
de Novellis et al. Molecular Pain 2011, 7:7
http://www.molecularpain.com/content/7/1/7
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polysynaptic pathway.
Indeed, even if the glutamatergic BLA projection to
GABAergic mPFC inter
could explain the BLA-driven inhibitory responses in
about 80% of the PL/IL pyramidal neurons in normal
conditions [81,82], it remains to be determined why the
excitatory/inhibitory cell populations ratio shifted drama-
tically in favour of the excitatory cells in the SNI pain
m o d e l .O n ep o s s i b i l i t yc o u l db eas t r e n g t h e n e dd i r e c t
connection between excitatory glutamatergic BLA
impinging on pyramidal neurons of PL/IL cortex rather
than on the inhibitory interneurons [85-87], caused by
SNI-induced proliferation of mPFC pyramidal neuron
dendrites [16]. Alternatively, another possible explanation
might be that the increased SNI-induced endovanilloid
tone, i.e. the over-expression of the TRPV1 channel, may
lead to the increased release of glutamate in the PL/IL
cortex, since TRPV1 activation is well known to be
coupled to enhanced glutamate release in the brain [88].
Indirect evidence supporting this possibility comes from
the present finding that SNI was also accompanied by
increased FAAH expression and the subsequent decrease
of the levels of the endocannabinoid/endovanilloid ana-
ndamide in the PL/IL cortex, as well as by an increase in
the levels of the endocannabinoid 2-AG. These latter
events might represent an adaptive mechanism aiming at
providing a negative feed-back control on the putative
TRPV1-mediated stimulation of glutamate release, since
anandamide is an endogenous activator of TRPV1, and
Figure 9 Effects of a single injection of vehicle, AA-5-HT (0.1-0.25-1 nmol) (A), AM251 (0.25-0.5 nmol) (B), AM251+AA-5-HT (C), I-RTX
(0.25-0.5-1 nmol) (D) or URB 597 (1-2-4 nmol) (E) on mechanical withdrawal threshold (mean ± S.E.M.) in spared nerve injury (SNI)
rats. Each point represents the mean ± S.E.M. of 8-10 rats per group. *p < 0.05 vs SNI/veh.
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Page 15 of 192-AG, which is inactive at TRPV1, may instead inhibit
glutamate release by acting as a retrograde signal at pre-
synaptic CB1 receptors. Alternatively, the stimulation by
2-AG of presynaptic CB1 receptors on GABAergic fibers
might contribute to reduce inhibitory signalling in the
PL/IL cortex, even though we did not observe here any
reduction in extracellular GABA levels in microdyalisates
from this brain region of SNI rats. Mechanistic studies in
mice with SNI are under way in order to investigate the
role of the endocannabinoid and endovanilloid system in
the enhanced excitatory vs. inhibitory signalling observed
here in SNI rats.
It is worth noting that a relatively short temporal win-
dow (7 days after SNI) was sufficient to produce the
observed morphological, neurochemical and functional
changes. These data are consistent with previous evi-
dence of increased NMDA receptor subunit NR2B in
the cingulate cortex of mice with persistent pain [89], as
well as with the reported synaptic proliferation on basal
dendrites of pyramidal neurons in the mPFC cortex in
SNI rats [16]. Such a morpho-functional reorganization
at the neuron basal dendrite level would indicate a spe-
cific long-lasting neuro-adaptive process aiming at
straightening the intra-cortical circuits, more than the
extra-cortical ones, in a way that such an increased local
spine density would wrongly integrate inputs converging
in this area.
A further consideration concerns the evidence that the
current data from 7-day treated SNI rats do not seem to
be consistent with data obtained in patients suffering
from neuropathic pain, in whom atrophy of the limbic
prefrontal cortex was reported [10]. However, as pre-
viously suggested by Metz et al. [16], it is possible that
this neuropathic pain model and the short period of
observation (which in fact requires a longer interval of
time in order to induce apoptosis or glutamate-mediated
excitotoxicity) did not allow us to note any apparent
neurodegeneration. Indeed there is no reason to exclude
the possibility that following a longer period of over-
excitation, increased spine number and NMDA receptor
currents may lead to increased glutamatergic excitotoxi-
city and apoptosis.
Based on the over-expressed endocannabinoid/endova-
nilloid biomarkers and elevated glutamate levels, we
decided to perform in SNI rats a repeated daily systemic
treatment with AA-5-HT, which we had previously
demonstrated to produce anti-allodynic and anti-
hyperalgesic effects in the chronic constriction injury
(CCI) neuropathic pain model via both indirect activa-
tion/desensitization of TRPV1 and activation of cannabi-
noid CB1 receptors, following elevation of AEA and
2-AG levels, and direct TRPV1 receptor antagonism
[49]. Indeed, AA-5-HT exerts its analgesic effect in
three ways: i) antagonism of TRPV1 receptors involved
in thermal hyperalgesia, ii) desensitization of TRPV1-
expressing nociceptors involved in mechanical allody-
nia and iii) indirect agonism at cannabinoid CB1
receptors in the CCI model of neuropathic pain [49].
Here we report that AA-5-HT treatment was able to
prevent mechanical allodynia and modulate both inhi-
bitory and excitatory transmission in the BLA-mPFC
pathway. Intriguingly, the relative efficacy of the effects
of intra-PL/IL cortex microinjections of selective vanil-
loid (I-RTX) or FAAH (URB597) inhibitors or of the
“hybrid” compound, AA-5-HT, underline the impor-
tance of concentrating two activities in one single
molecule to significantly reduce allodynia and further
validate the critical role played by TRPV1 and FAAH
in specific mPFC sub-regions involved in pain modula-
tion. Several previous studies have reported that the
PL/IL cortex, which corresponds to the dorsal-lateral
prefrontal cortex in humans, plays a crucial role in
pain processing [10,89-93], and emerging imaging stu-
dies show that this brain region is involved in pain
inhibition in humans [93]
Furthermore, since the treatment with AA-5-HT led
to restore normal neuronal activity in the BLA-mPFC
pathway, these data support our hypothesis that the
over-expressed TRPV1 channel, which seems to be
mainly present in glutamatergic neurons, is one of the
mechanisms that in SNI rats activate pathways (likely
calcium-dependent) associated with cell plasticity
[94,95]. In agreement with the TRPV1-induced neural
plasticity described previously [42,96-98], it is possible
that functional re-organization mediated by glutamate/
endovanilloid and GABA/endocannabinoid signalling
can also occur following TRPV1 channel over-stimula-
tion and the consequent increased release of glutamate
in the PL-IL cortex of SNI rats in both identified popu-
lations of mPFC neurons.
In conclusion, this study shows that in pressoceptive
responding populations of mPFC neurons, the pre-
viously described BLA®mPFC(-) and BLA®mPFC(+)
neurons [53], may undergo profound reorganization
related to neuropathic pain. The present findings indi-
cate that a relatively short period of SNI-induced neuro-
pathy (7 days) may be sufficient to up-regulate the
endovanilloid/endocannabinoid machinery in the PL/IL
cortex, implying that disruptions in the mPFC endova-
nilloid/endocannabinoid system might impair behaviours
mediated by the BLA-mPFC circuits. Since similar
alterations have been shown in corresponding neural
circuitries in chronic pain subjects, it may be conceiva-
ble to speculate that the changes we have observed here
could be a contributing factor to emotional and cogni-
tive disturbances associated with chronic pain disorders.
Local or systemic pharmacological manipulation of the
TRPV1 channel and the enzyme FAAH with the hybrid
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Page 16 of 19drug AA-5-HT proves to inhibit allodynia/hyperalgesia
and normalize the imbalance between excitatory and
inhibitory responses in the mPFC neurons. As such, psy-
chopharmacological therapies designed to normalize
endovanilloid/endocannabinoid transmission in the
mPFC glutamatergic terminals may prove useful in alle-
viating the symptoms and central sequelae of neuro-
pathic pain syndromes.
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